anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
METADATE CD has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction [see Warnings and Precautions (5.1)]. METADATE CD can be diverted for non-medical use into illicit channels or distribution.

Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.

Misuse and abuse of methylphenidate may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including METADATE CD, can result in overdose and death [see Overdosage (10)], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Cervical cancer (CC) remains one of the most severe global health challenges affecting women, primarily due to persistent infection with high-risk human papillomavirus (HPV) subtypes, particularly with HPV16 and HPV 18. Effective detection of these high-risk HPV strains is crucial for CC prevention. Current screening programs for HPV DNA include PCR and in situ hybridization, which are accurate and sensitive. However, these approaches demand a high level of expertise, along with expensive instruments and consumables, thus hindering their widespread use. Therefore, there is a compelling demand to develop an efficient, straightforward, and cost-effective method. Herein, we propose a lateral flow immunoassay (LFIA) method based on Au@PdPt nanoparticles for the simultaneous detection and genotyping of HPV16 and HPV18 within 15 min. This innovative approach allows for qualitative assessment by the naked eye and enables semi-quantitative detection through a smartphone. In this study, under optimal conditions, the qualitative visual limits of detection (vLOD) for HPV16 and HPV18 reached 0.007 nM and 0.01 nM, respectively, which were 32-fold and 20-fold more sensitive than conventional AuNPs-LFIA for HPV16 and HPV18, respectively. Meanwhile, semi-quantitative limits of detection (qLOD) for HPV16 and HPV18 were 0.05 nM and 0.02 nM, respectively. In conclusion, our formulated approach represents a significant step forward in HPV detection and genotyping, with the potential to enhance accessibility and effectiveness in the early diagnosis of CC at the point of care and beyond.
The participant is asked to focus on the image or, failing that, the sensory representation representing the worst aspect of the targeted intrusive thought for 10 seconds and visually follow the horizontal displacement of a white dot (Ø 1cm) on the black screen at a constant speed of 1.2 Hz. This speed, implying the displacement of 1.2 left-right-left cycles per second, targets the saturation of working memory.
PURPOSE:To prepare the UV light-absorbing resin particles comprising a specific reactive benzotriazole compound and a (meth)acrylic compound and/or a styrenic compound and free from skin irritation. CONSTITUTION:UV light-absorbing resin particles are formed from a resin comprising repeating units derived from a reactive benzotriazole compound of the formula and repeating units derived from a (meth)acrylic compound. Since the benzotriazole skeletons having the UV light-absorbing action are combined with the resin, the UV light-absorbing agent causing skin roughness is not eluted, even when the particles contact with an oily base agent for cosmetics. A body pigment or pearl pigment whose surface is at least partially coated with the UV light-absorbing resin particles does not irritate skin and exhibits a good UV light-absorbing action. The luster of the pigment can thereby be controlled by changing the surface-covering rate of the pigment. Further, the coated pigment may be added to cosmetics.
PURPOSE: To investigate the value of ultrasound-guided percutaneous nephrostomy and nephrostomy tube replacement for treating a solitary kidney with hydronephrosis due to renal tuberculosis.
METHODS: Clinical data of patients with a solitary kidney with hydronephrosis caused by renal tuberculosis who underwent ultrasound-guided percutaneous nephrostomy in our hospital from January 2011 to December 2022 were retrospectively analyzed. The associated success rate and complications were statistically analyzed, pre- and post-catheterization changes in serum creatinine and blood urea nitrogen levels were compared, success rate and complications of nephrostomy tube replacement in patients with long-term catheterization were statistically analyzed, and the impact of long-term catheterization on patient life was investigated.
RESULTS: Overall, 32 patients aged 17-75 years (average age: 44.1 ± 16.9 years) underwent ultrasound-guided percutaneous nephrostomy. Sixty-three punctures were performed; the puncture success rate was 100%. The levels of serum creatinine and blood urea nitrogen of patients decreased after catheterization, and the differences between the pre-catheterization and post-catheterization were significant (P < 0.05). There were 1, 3, and 12 cases of serious, minor, and fistula-related complications, respectively. The mean duration of the indwelling catheter was 56.7 ± 36.2 (range, 13-120) months. The number of nephrostomy tube replacements was 344 times, and the success rate was 100%. All patients could take care of the puncture point by themselves.
CONCLUSION: Ultrasound-guided percutaneous nephrostomy and nephrostomy tube replacement have a high success rate and few complications, which can improve the renal function of patients. It is of great value for treating a solitary kidney with hydronephrosis caused by renal tuberculosis.
This group will complete a 16-week standard behavioral weight control intervention in which they will be asked to consume \>50% of their daily energy goal before 3PM. To do so, they will complete weekly experiential learning sessions in conjunction with the SBT lessons.
Placebo matching the SHEN26 capsule. 10 oral doses twice daily (after breakfast and dinner; Q12h±2h).
FIELD: medicine. ^ SUBSTANCE: group of inventions refers to medicine, namely to ophthalmology, and can be used in treatment of eye diseases. The methods under the invention include the introduction of a complement pathway inhibitor with C2a, C3a, C5, C5a, C5b, C7, C8 or C9 inactivation. Also, the methods under the invention concern the inhibition of an alternative complement pathway by introducing Factor H or its functional peptide, or siRNA specific for a complement pathway protein, or nucleic acid coding the complement pathway inhibitor. ^ EFFECT: use of the inventions allows treating eye diseases due to inactivating the classical and alternative complement pathways. ^ 39 cl, 1 ex
A dressing for a wound site and method of using same. The dressing includes a first layer comprising a butyl-cyanoacrylate adhesive applied directly to the wound site and extending a distance beyond the wound site to form a peripheral edge. The dressing also includes a second layer comprising a butyl-cyanoacrylate adhesive applied directly to the first layer and overlapping the peripheral edge of the first layer a distance. In a moderate-tension wound the second layer extends the entire area of the first layer, but also extends a distance beyond the peripheral edge. Also provided is a dressing and method for treating high-tension wounds. First and second layers of a 1-butyl cyanoacrylate 16 adhesive are applied to a short, high-tension wound, with the first and second layers covering the wound and extending to at least about 2.5mm (0.0984in.) from each side of the wound. The first layer is allowed to set and polymerize before the second layer of 1-butyl cyanoacrylate is applied. The second layer extends at least about 2.5mm (0.0984 in.) beyond each edge of the first layer. In the case of a long, high-tension wound, a third layer is applied after the first and second layers are allowed to set and polymerize. The third layer is at least about 2.5mm (0.0984in.) wide and is substantially perpendicular to the first and second layers. The third layer may occur intermittently every 2.5cm (0.984in.) over the length of the wound, and preferably extends at least about 5mm (0.197in.) beyond the edge of the first layer.
Two different lots of GDC-0032 active pharmaceutical ingredient (API) capsule formulation will be administered orally in crossover fashion over 2-TP to 20 participants having 10 hour fasting from food. Participants will receive one 3 mg capsule in TP-A and one 3 mg capsule in TP-B after 14 to 20 days washout period.
The efficacy of XHANCE for Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) was evaluated in two 24-week randomized, double-blind, parallel-group, multicenter, placebo-controlled trials in 555 adults 18 years and older (Trial 3 [NCT03960580] and Trial 4 [NCT03781804]). Trial 3 included 223 patients with CRSsNP and Trial 4 included 332 patients with either CRSsNP (N=124) or CRSwNP (N=208). While Trial 4 included CRSwNP patients, efficacy results from Trials 3 and 4 are presented for CRSsNP patients only. 

In both trials, patients were randomized 1:1:1 to receive XHANCE 186 mcg twice daily, XHANCE 372 mcg twice daily, or placebo, all administered nasally for 24 weeks. All patients enrolled in Trial 3 and Trial 4 had at least 2 active nasal symptoms (congestion/obstruction, discharge, facial pain or pressure, reduction or loss of smell) with a minimum nasal congestion score ≥1.5 out of 3 and a baseline CT scan showing ≥25% opacification of both ethmoid and at least 1 maxillary sinus. Refer to Table 4 for the demographic and baseline characteristics of all randomized CRSsNP patients in Trials 3 and 4.

In both trials, the coprimary efficacy endpoints were 1) change from baseline at Week 4 in the composite symptom score (CSS) as determined by patients using a daily diary and 2) change from baseline at Week 24 in percent opacified sinus volume. CSS was the sum of the individual nasal symptom scores for congestion/obstruction, facial pain/pressure, and nasal discharge, each rated by the patient on a 0 to 3 categorical severity scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) in the morning immediately prior to the next dose. Sinus opacification was measured by CT scan and scored using a 3-dimensional computer-assisted volumetric assessment using software to quantify the average percent of opacified volume in the ethmoid and maxillary sinuses. 

Efficacy was demonstrated for both coprimary endpoints (CSS and percent opacified sinus volume) for XHANCE 186 mcg twice daily and XHANCE 372 mcg twice daily. Refer to Table 5 for coprimary endpoint results. Improvements demonstrated in CSS at Week 4 with either dose of XHANCE remained at Weeks 8 and 12.

Secondary efficacy endpoints included change from baseline in individual symptoms of the CSS (nasal congestion, nasal pain/pressure, and nasal discharge) at Week 4. Refer to Table 6 for individual symptom score results.

Acute Exacerbations

Acute exacerbations of chronic rhinosinusitis (AECRS), defined as a worsening of symptoms that required escalation of treatment (e.g., antibiotics, oral steroids, acute care visits), was assessed in the CRSsNP patients from pooled data (Trials 3 and 4) through Week 24. The rate of AECRS was reduced by 53% among patients in each XHANCE treatment group versus placebo. This was derived from incidence rate ratios of 0.47 (95% CI: 0.21, 1.08) and 0.47 (95% CI: 0.20, 1.09) among patients using XHANCE 186 mcg and 372 mcg twice daily versus placebo, respectively; which were not statistically significant.
Arsenic trioxide (ATO) is a potent and highly effective chemotherapeutic agent for the treatment of acute promyelocytic leukemia. However, the clinical use of ATO is hampered by different cardiopathologic outcomes, such as arrhythmia and heart failure. Berberine has several beneficial effects because of its antioxidant activity; however, the potential cardioprotective function of this alkaloid against arsenic-induced cardiac toxicity has not been fully investigated. In this study, we evaluated the effect of ATO in rat heart tissue and the effect of berberine nanoparticles (NB) on cardiac enzyme levels, oxidative stress (OS) indices, and histopathological changes in heart tissue. Thirty Wistar rats were randomly allocated into five groups (n = 6): (1) Control animals that received 0.5 cc saline via gavage, (2) ATO group (4 mg/kg), (3) ATO + NB (2.5 mg/kg), (4) ATO + NB (5 mg/kg), and (5) ATO + NB (10 mg/kg) groups. Treatments were administered intraperitoneally for 45 days. Cardiac enzymes and OS biomarkers in heart tissue were measured. Histopathological examination of the heart tissue was also conducted at the end of the study. ATO injection significantly increased cardiac enzyme levels and OS biomarkers in rat's heart tissue. It also changed the histological features of the heart. NB administration significantly decreased the serum and tissue levels of cardiac enzyme and OS biomarkers in ATO-exposed animals (p < 0.05) and improved myocardial structural damage. NB, potent antioxidant, can reduce the unfavorable effects of ATO in rat heart tissue by balancing OS markers.
BACKGROUND AND OBJECTIVES: The extension of the systemic inflammatory response observed after cardiopulmonary bypass (CPB) in cardiac surgery is associated to postoperative pulmonary dysfunction degree. The leukocyte depletion during CPB can modify that response. The aim of this study was to evaluate the effects of leukocyte filtering on the inflammatory response and lung function in patients undergoing coronary artery bypass grafting.

METHODS: After approval by the institutional ethical committee, a prospective randomized study was performed to compare nine patients undergoing coronary artery bypass grafting (CABG) using leukocyte filtration in the arterial line (LG-6, Pall Biomedical Products) and eleven others submitted to standard CPB. Chest CT, oxygenation analysis and a complete leucocyte count were performed before surgery. After intravenous anesthesia induction, patients were mechanically ventilated with tidal volume of 8 mL.kg-1, with FiO2 0.6, and PEEP of 5 cm H2O, except during CPB. Haemodynamic data, PaO2/FiO2, shunt fraction, interleukins, elastase and myeloperoxidase were evaluated before and after CPB, at the end of surgery, 6, 12 and 24 hours after surgery. Chest CT was repeated on the first postoperative day. Data were analyzed using two-factor ANOVA for repeated measures.
Weekly 17 alpa hydroxyprogesterone caproate (17p) injections plus Omega 3 supplements, 4 capsules per day for up to 5 weeks. Each capsule contained 200 mg of docosahexaenoic acid (DHA) and 300 mg of eicosapentaenoic acid (EPA).
NevustoMel is an international multicentric retrospective cohort study with molecular and experimental design. It will involve the genomic characterization of cell-free DNA and affected tissues from patients. Methylomics and single-cell multi-omics will be used to identify co-existing molecular (transcriptional and epigenomic) states at single-cell level and will be generated from affected tissues. These results will be exploited using machine learning-assisted integration of multi-modal transcriptomics, epigenomics and spatial information. Integrated analyses of single-nucleus RNA sequencing from a selection of frozen tissues and spatial transcriptomics on formalin-fixed paraffin-embedded samples will allow the comparison of the findings to ground-state Human Developmental Cell Atlas data. Distinctions will be validated either with in situ hybridization (such as RNA sequencing) or immunostaining on test cohort tissues. These results will be complemented with in vitro functional analyses, high throughput sequencing and bioinformatic analyses.
Patients with EBV+ PTLD following SOT who were R/R to rituximab and chemotherapy will receive IV infusion of transplant donor-derived EBV-CTLs at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
PROBLEM TO BE SOLVED: To obtain a mineral absorption-stimulating agent comprising the essences of the seeds of a leguminous plant, excellent in the effect for stimulating the absorption of minerals, especially calcium, high in safety, and capable of being continuously administered for a long period, when used as a medicine composition. SOLUTION: This mineral absorption-stimulating agent comprises the essence of the seeds of a leguminous plant (preferably soybean). The essence is preferably the dry ground product of the soybean, an extract obtained by extracting a mineral absorption-stimulating component from the soybean, its solvent- removed product, or a purified product fractionated from the extract. The extraction of the soybean is preferably performed by immersing the raw soybean or a soybean processed product in a 1-100 fold volume of a (non)polar solvent. When the absorption-stimulating agent is used as a medicine composition, the absorption-stimulating agent is preferably orally administered as a dose of 0.1-100g once to several times a day for an adult. When a mineral-supplying agent is added to the composition, a calcium-supplying agent is preferably used as the supplying agent.
Participants with AC mCRPC in Cohort E will receive pembrolizumab 200 mg IV on Day 1 Q3W, and lenvatinib 20 mg PO QD continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
Recommended dose reductions for adverse reactions for use of KRAZATI as a single agent or in combination with cetuximab are outlined in Table 1. If adverse reactions occur, a maximum of two dose reductions are permitted. Permanently discontinue KRAZATI in patients who are unable to tolerate 600 mg once daily.

Refer to the cetuximab prescribing information for dose modifications for adverse reactions associated with cetuximab.

When KRAZATI is administered in combination with cetuximab, withhold or permanently discontinue cetuximab when KRAZATI is withheld or permanently discontinued.

Treatment with KRAZATI as a single agent may be continued if cetuximab is permanently discontinued. [see Clinical Pharmacology (12.1), Clinical Studies (14.2)].

The recommended dosage modifications for adverse reactions are provided in Table 2.
BACKGROUND: The purpose of this study was to investigate the long-term mortality rates of patients with obstructive sleep apnea (OSA) who received an overnight polysomnogram (PSG) for obtaining the diagnosis and to determine the relationship between PSG parameters and overall mortality.
METHODS: Between 2007 and 2013, patients who had overnight PSG and were diagnosed with OSA were included in the study. Factors which are thought to influence mortality were assessed for 5-year and overall survival using the log rank test and Kaplan-Meier survival curves. Using multivariable Cox regression analysis, a model was constructed for factors influencing 5-year and overall survival.
RESULTS: A total of 762 patients with a mean age of 52.7 (±10.8) and a dominance of men (74.7%) were studied. Gender, OSA severity subgroups, and apnea hypopnea index (AHI) were not statistically significantly associated with either 5-year or overall mortality (p<0.05 for both). Age, having a cardiovascular comorbidity, proportion of rapid eye movement (%REM), and total sleep time with an oxyhemoglobin saturation of less than 90% (T90) all showed a significant correlation with overall all-cause mortality in the model. For 5-year mortality and overall mortality, the hazard ration (HR) for T90 was 3.6 (95% CI (1.6-8.0) p=0.001) and 3 (95% CI (1.6-5.7) p=0.001), respectively.
CONCLUSION: The study findings suggest that not AHI but PSG parameters of hypoxia, mainly T90, having cardiovascular comorbidity, and %REM sleep were significant risk factors for all-cause mortality in patients with OSA. The association of OSA, hypoxia, and mortality is an area that deserves further study.
Individualized diet prescription following food record, indirect calorimetry (for energy requirement) and body composition assessments. repeat assessments after 12 weeks on interventional diet.
Twenty-six consecutive patients undergoing allogeneic HSCT for hematological malignancies were studied. All patients were in stable clinical conditions at the time of study. All patients received a myeloablative conditioning regimen either including or not including total body irradiation. Spirometry, lung volumes, FOT and lung CT scan were obtained before the start of conditioning treatment and, approximately, two months after HSCT. On each study day, all the above measurements were taken before and 30 min after inhaling four consecutive albuterol doses, of 100 mcg each, through a valved-holding chamber. DLco was measured only after bronchodilator inhalation.
Malignant tumors are common diseases and frequently encountered diseases and can seriously intimidate the health and the life of human beings. For the past few years, the disease rate of tumors is increased continuously and gradually becomes an archenemy of human health, and the malignant tumors have the death rate second only to cardiovascular diseases. According to a WHO report, the number of patients with malignant tumors reaches 1200 thousands per year all over the world, and the disease rate of tumors is increased by 50 percent all over the world in 2020. The disease rate of tumors is prodigious in China, and the death rate of people for malignant tumors is second in all diseases. The technology for extracting Chinese actinidia root antitumor active sites belongs to the technical field of traditional Chinese medicines, in particular to a method for extracting and separating Chinese actinidia root general flavone. The actinidia root general flavone comes from roots of Actinidia argutaor guta (Sibe.et Zucc.) Planch.ex Miq, effective component groups with flavone mother nuclide components are extracted, separated and purified, experimental researches prove that the Chinese actinidia root general flavone has obvious antitumor function, low toxicity and obvious medical effect.
These patients will have diagnosed with iron deficiency anaemia and been prescribed oral iron supplements as part of their treatment from their doctor. This will be in accordance with the NICE guidelines; 200mg capsules containing 65mg elemental iron, 2-3 times a day for a period of atleast 1 month.
Participants will receive cobimetinib capsules and pictilisib capsules from Days 1 to 7 and then from Days 15 to 21 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1B. Participants will be off study drugs from Days 8 to 14 and from Days 22 to 28. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with KRAS mutant endometrioid carcinoma.